Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Start CPAP-terapi hos patienter med obstruktiv søvnapnø efter atrial fibrillation ablation (STOP-AFib)

30. september 2026 opdateret af: Beijing Anzhen Hospital

Start CPAP-terapi hos patienter med obstruktiv søvnapnø efter atrieflimmer-ablation: Et multicenter, åbent, randomiseret klinisk forsøg

Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.

This study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.

Participants will:

  • Be randomly assigned to either the CPAP group or the usual care group.
  • If in the CPAP group, use a CPAP device for 12 months.
  • Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months after randomization.
  • Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after randomization.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Atrial fibrillation (AF) is a common sustained cardiac arrhythmia, with recurrence rates of 20-45% after catheter ablation. Obstructive sleep apnea (OSA) is a common comorbidity and an important modifiable risk factor for post-ablation AF recurrence. Continuous positive airway pressure (CPAP) is the standard therapy for OSA, but its effect on reducing AF recurrence after ablation remains uncertain.This study aims to evaluate whether, in patients with OSA and AF who undergo catheter ablation, the postoperative CPAP treatment can increase the rate of no recurrence of atrial arrhythmia within one year compared to usual treatment. This prospective, multicenter, open-label, parallel-group randomized controlled trial will be conducted at approximately 20 centers in mainland China. Approximately 658 adults aged 18-75 years with persistent AF and diagnosed OSA who have successfully undergone first-time catheter ablation will be enrolled.

After confirmation of eligibility and informed consent, participants will be randomized in a 1:1 ratio to receive either CPAP therapy plus usual care or usual care alone. CPAP therapy will be provided for 12 months, with treatment parameters determined by pressure titration, and adherence monitored using device-recorded data. Participants in the usual care group will receive standard AF management and standardized education regarding OSA; additional OSA treatments outside the study protocol will be permitted and documented.All participants will receive guideline-directed medical therapy for AF.

Follow-up will last at least 12 months, with assessments at approximately 1, 3, 6, and 12 months after randomization. Atrial arrhythmia monitoring will be performed primarily using ambulatory ECG recorders.

The primary outcome is freedom from atrial arrhythmia recurrence within 12 months after randomization. Secondary outcomes include atrial arrhythmia recurrence patterns, arrhythmia-related interventions, atrial fibrillation burden, and changes in quality-of-life and psychological assessment scores.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

658

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Tianjin, Kina
        • Ikke rekrutterer endnu
        • Tianjin Medical University Second Hospital
        • Ledende efterforsker:
          • Xiaoyun Zhao, Professor
        • Kontakt:
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100029
        • Rekruttering
        • Beijing Anzhen Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Jiang Xie, Professor
        • Ledende efterforsker:
          • Shaoping Nie, Professor
        • Ledende efterforsker:
          • Deyong Long, Professor
      • Beijing, Beijing Municipality, Kina, 100730
        • Ikke rekrutterer endnu
        • Beijing Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Wei Gong, Professor
      • Beijing, Beijing Municipality, Kina, 102206
        • Ikke rekrutterer endnu
        • Peking University International Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Yanwen Jiang, Professor
      • Beijing, Beijing Municipality, Kina, 100020
        • Ikke rekrutterer endnu
        • Beijing Chaoyang Hospital, Capital Medical University
        • Kontakt:
          • Zhiling Zhao, Professor
          • Telefonnummer: +86-10-85231000
          • E-mail: cysleep@163.com
        • Ledende efterforsker:
          • Zhiling Zhao, Professor
      • Beijing, Beijing Municipality, Kina, 100035
        • Ikke rekrutterer endnu
        • Beijing Jishuitan Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Yang Cheng, Professor
    • Fujian
      • Fuzhou, Fujian, Kina, 350001
        • Ikke rekrutterer endnu
        • Fujian Medical University Union Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Xiangqi Chen, Professor
      • Fuzhou, Fujian, Kina, 350004
        • Ikke rekrutterer endnu
        • First Affiliated Hospital of Fujian Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Ningfang Lian, Professor
      • Zhangzhou, Fujian, Kina, 363000
        • Ikke rekrutterer endnu
        • Zhangzhou Hospital of Fujian Province
        • Kontakt:
        • Ledende efterforsker:
          • Li Lin, Professor
    • Guangxi
      • Nanning, Guangxi, Kina, 530021
        • Ikke rekrutterer endnu
        • People's Hospital of Guangxi Zhuang Autonomous Region
        • Kontakt:
        • Ledende efterforsker:
          • Mingming Zhao, Professor
    • Hebei
      • Langfang, Hebei, Kina, 065000
        • Ikke rekrutterer endnu
        • Langfang People's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Zengming Xue, Professor
      • Shijiazhuang, Hebei, Kina, 050000
        • Rekruttering
        • Shijiazhuang Great Wall Hospital of Integrated Traditional Chinese and Western Medicine
        • Kontakt:
          • Linyi Huang, Professor
          • Telefonnummer: +86-0311-85837801
          • E-mail: 496777551@qq.com
        • Ledende efterforsker:
          • Linyi Huang, Professor
      • Xingtai, Hebei, Kina, 055250
        • Rekruttering
        • The Ninth Hospital of Xingtai
        • Kontakt:
        • Ledende efterforsker:
          • Zhanwei Liu, Professor
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150086
        • Ikke rekrutterer endnu
        • Second Affiliated Hospital of Harbin Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Wei Meng, Professor
    • Henan
      • Shangqiu, Henan, Kina
        • Ikke rekrutterer endnu
        • Shangqiu First People's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Renshan Niu, Professor
      • Zhengzhou, Henan, Kina, 450052
        • Ikke rekrutterer endnu
        • The First Affiliated Hospital of Zhengzhou University
        • Kontakt:
        • Ledende efterforsker:
          • Gangqiong Liu, Professor
    • Hubei
      • Wuhan, Hubei, Kina, 430014
        • Ikke rekrutterer endnu
        • Wuhan No. 1 Hospital
        • Kontakt:
          • Zhihua Yu, Professor
          • Telefonnummer: +86 02785332144
          • E-mail: whyu027@163.com
        • Ledende efterforsker:
          • Zhihua Yu, Professor
      • Wuhan, Hubei, Kina, 430056
        • Ikke rekrutterer endnu
        • Wuhan Asia General Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Ning Man, Professor
    • Hunan
      • Changsha, Hunan, Kina, 410011
        • Ikke rekrutterer endnu
        • The Second Xiangya Hospital of Central South University
        • Kontakt:
        • Ledende efterforsker:
          • Ruoyun Ouyang, Professor
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210029
        • Ikke rekrutterer endnu
        • The First Affiliated Hospital of Nanjing Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Ning Ding, Professor
    • Jilin
      • Changchun, Jilin, Kina, 130021
        • Ikke rekrutterer endnu
        • The First Hospital of Jilin University
        • Kontakt:
          • Haibo Yuan, Professor
          • Telefonnummer: +86-431-88782222
          • E-mail: hyuan@jlu.edu.cn
        • Ledende efterforsker:
          • Haibo Yuan, Professor
    • Liaoning
      • Dalian, Liaoning, Kina, 116011
        • Ikke rekrutterer endnu
        • First Affiliated Hospital of Dalian Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Haiying Tang, Professor
      • Shenyang, Liaoning, Kina, 110004
        • Ikke rekrutterer endnu
        • Shengjing Hospital of China Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Li Xiao, Professor
      • Shenyang, Liaoning, Kina, 110001
        • Ikke rekrutterer endnu
        • First Affiliated Hospital of China Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Wenyang Li, Professor
    • Shandong
      • Dongying, Shandong, Kina, 257034
        • Ikke rekrutterer endnu
        • Shengli Oilfield Central Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Xiangfei Liu, Professor
      • Linyi, Shandong, Kina, 276003
        • Ikke rekrutterer endnu
        • Linyi People's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Li Wei, Professor
    • Shanxi
      • Taiyuan, Shanxi, Kina, 030001
        • Ikke rekrutterer endnu
        • Second Hospital of Shanxi Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Xiaoling Gao, Professor
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300222
        • Ikke rekrutterer endnu
        • Tianjin Chest Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Fang Zhao, Professor
    • Yunnan
      • Kunming, Yunnan, Kina
        • Ikke rekrutterer endnu
        • Yan'an Hospital of Kunming City
        • Kontakt:
          • Xia Jiang, Professor
          • Telefonnummer: +86-0871-63211073
          • E-mail: 378972370@qq.com
        • Ledende efterforsker:
          • Xia Jiang, Professor
    • Zhejiang
      • Ningbo, Zhejiang, Kina, 315010
        • Ikke rekrutterer endnu
        • First Affiliated Hospital of Ningbo University
        • Kontakt:
        • Ledende efterforsker:
          • Maoqing Tong, Professor

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Patients must meet all of the following conditions to be eligible for the study:

  • Age 18-75 years.
  • Patients with persistent AF who received catheter ablation for the first time.
  • Diagnosed with OSA.
  • Able to tolerate CPAP therapy.
  • Capable of understanding and complying with the study protocol.
  • Willing to sign the informed consent form.

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from the study:

  • Secondary AF.
  • Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).
  • Left ventricular ejection fraction < 30%.
  • Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).
  • Pregnant or breastfeeding women.
  • History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.
  • History of stroke or transient ischemic attack within 6 months prior to screening.
  • Perioperative complications related to the ablation procedure occurring prior to randomization.
  • Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.
  • Life expectancy < 1 year.
  • Central sleep apnea.
  • Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI > 30kg/m² and awake PaCO₂ > 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with > 1 episode of respiratory failure or hypercapnia.
  • Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.
  • Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.
  • Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.
  • Current participation in other drug or device trials.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: CPAP Group

Usual care combined with CPAP therapy.

Participants receive CPAP therapy provided by the research team. Treatment parameters are determined following auto-titrating or manual pressure titration. Prior to treatment initiation, participants receive training on device usage, mask fitting and adjustment, equipment cleaning and maintenance, and data transmission methods. Study physicians and technicians provide support to address any CPAP-related discomfort. 'Good adherence' is defined as device usage of ≥ 4 hours per night on ≥ 70% of days.

Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives.

Aktiv komparator: Usual Care Group

Standard of care for atrial fibrillation and usual care for OSA (health education). Researchers advise participants to visit sleep centers or pulmonology departments for further assessment/treatment at their own discretion, but do not intervene in their choice of OSA therapy or provide the study CPAP device.

Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of freedom from atrial arrhythmia recurrence.
Tidsramme: Within 12 months

Recurrence is defined as a composite of:

  1. Any documented atrial arrhythmia (AF / Atrial Tachycardia [AT] / Atrial Flutter [AFL]) lasting 30 seconds after a 3-month blanking period;
  2. Use of Class I or III AADs after the 3-month blanking period;
  3. Cardioversion performed after the 3-month blanking period;
  4. Repeat catheter ablation performed at any time.
Within 12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Forekomsten af dokumenteret atrieflimren/-flagren/-takykardi (AF/AFL/AT) med en varighed på ≥30 sekunder.
Tidsramme: Inden for 12 måneder (efter en 3-måneders blankingsperiode).
Inden for 12 måneder (efter en 3-måneders blankingsperiode).
Forekomsten af dokumenteret AF, der varer ≥30 sekunder.
Tidsramme: Inden for 12 måneder (efter en 3-måneders blankingperiode).
Inden for 12 måneder (efter en 3-måneders blankingperiode).
Forekomsten af dokumenteret AT, der varer ≥30 sekunder.
Tidsramme: Inden for 12 måneder (efter en 3-måneders blankingperiode).
Inden for 12 måneder (efter en 3-måneders blankingperiode).
Forekomst af dokumenteret AFL, der varer ≥30 sekunder.
Tidsramme: Inden for 12 måneder (efter en 3-måneders blankingperiode).
Inden for 12 måneder (efter en 3-måneders blankingperiode).
Andel af patienter, der bruger klasse I eller III antiarytmiske lægemidler.
Tidsramme: Inden for 12 måneder (efter en 3-måneders blankingperiode).
Inden for 12 måneder (efter en 3-måneders blankingperiode).
Andelen af patienter, der gennemgår kardioversion.
Tidsramme: Inden for 12 måneder (efter en 3-måneders blankingperiode).
Inden for 12 måneder (efter en 3-måneders blankingperiode).
Andel af patienter, der gennemgår gentagen kateterablation.
Tidsramme: Inden for 12 måneder.
Inden for 12 måneder.
AF-byrde
Tidsramme: Inden for 12 måneder.
Inden for 12 måneder.
Change in quality of life assessed by the Atrial Fibrillation Effect on Quality-of-Life questionnaire.
Tidsramme: Baseline, Month 12.

Scores range from 0 to 100, where higher scores indicate a better quality of life.

Baseline, Month 12.
Change in anxiety and depression assessed by the Hospital Anxiety and Depression Scale.
Tidsramme: Baseline, Month 12.

Scores for both the anxiety and depression subscales range from 0 to 21, where higher scores indicate worse anxiety and depression.

Baseline, Month 12.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

12. maj 2026

Primær færdiggørelse (Anslået)

31. januar 2029

Studieafslutning (Anslået)

31. januar 2029

Datoer for studieregistrering

Først indsendt

25. februar 2026

Først indsendt, der opfyldte QC-kriterier

25. februar 2026

Først opslået (Faktiske)

2. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. september 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • KS2025046
  • 2024ZD0529100 (Andet bevillings-/finansieringsnummer: Development Center for Medical Science & Technology National Health Commission of the People's Republic of China)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .